VTGN VistaGen Therapeutics Inc
Price (delayed)
$2.39
Market cap
$68.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.48
Enterprise value
-$4.02M
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and
Highlights
The company's debt fell by 24% YoY and by 4.5% QoQ
VistaGen Therapeutics's EPS has soared by 58% YoY but it has decreased by 19% from the previous quarter
VTGN's quick ratio has dropped by 70% year-on-year and by 29% since the previous quarter
The net income has declined by 48% year-on-year and by 20% since the previous quarter
Key stats
What are the main financial stats of VTGN
Market
Valuations
Earnings
Shares outstanding
28.86M
Market cap
$68.98M
Enterprise value
-$4.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
105.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.76
Revenue
$698,300
Gross profit
$698,300
Operating income
-$52.84M
Net income
-$47.3M
EBIT
-$47.3M
EBITDA
-$46.68M
Free cash flow
-$39.36M
Per share
Balance sheet
Liquidity
EPS
-$1.48
EPS diluted
-$1.48
Free cash flow per share
-$1.28
Book value per share
$2.91
Revenue per share
$0.02
TBVPS
$3.01
Total assets
$92.31M
Total liabilities
$11.19M
Debt
$1.71M
Equity
$81.12M
Working capital
$80.32M
Debt to equity
0.02
Current ratio
9.35
Quick ratio
9.2
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
-6,684.9%
Gross margin
100%
Net margin
-6,774.2%
Operating margin
-7,566.5%
Return on assets
-43.8%
Return on equity
-48.1%
Return on invested capital
-629.1%
Return on capital employed
-57.2%
Return on sales
-6,773%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTGN stock price
How has the VistaGen Therapeutics stock price performed over time
Intraday
2.14%
1 week
-9.47%
1 month
-11.48%
1 year
-55.74%
YTD
-18.98%
QTD
-4.4%
Financial performance
How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$698,300
Gross profit
$698,300
Operating income
-$52.84M
Net income
-$47.3M
Gross margin
100%
Net margin
-6,774.2%
The operating margin has dropped by 133% year-on-year and by 45% since the previous quarter
The company's net margin has shrunk by 120% YoY and by 50% QoQ
The company's operating income has shrunk by 56% YoY and by 16% QoQ
The net income has declined by 48% year-on-year and by 20% since the previous quarter
Growth
What is VistaGen Therapeutics's growth rate over time
Valuation
What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.82
P/S
105.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-5.76
VistaGen Therapeutics's EPS has soared by 58% YoY but it has decreased by 19% from the previous quarter
The price to book (P/B) is 74% lower than the 5-year quarterly average of 3.1 and 20% lower than the last 4 quarters average of 1.0
The equity has decreased by 34% YoY and by 13% QoQ
VistaGen Therapeutics's revenue has decreased by 33% YoY and by 20% QoQ
The price to sales (P/S) is 7% lower than the last 4 quarters average of 110.2
Efficiency
How efficient is VistaGen Therapeutics business performance
VistaGen Therapeutics's ROS has plunged by 120% YoY and by 50% from the previous quarter
The ROE has increased by 33% YoY but it has decreased by 32% from the previous quarter
The company's return on invested capital rose by 32% YoY and by 9% QoQ
The company's return on assets fell by 30% QoQ but it rose by 29% YoY
Dividends
What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTGN.
Financial health
How did VistaGen Therapeutics financials performed over time
The current ratio has plunged by 70% YoY and by 30% from the previous quarter
VTGN's quick ratio has dropped by 70% year-on-year and by 29% since the previous quarter
The company's debt is 98% lower than its equity
The equity has decreased by 34% YoY and by 13% QoQ
The company's debt fell by 24% YoY and by 4.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.